Table of Contents
ISRN Endocrinology
Volume 2014, Article ID 530830, 3 pages
http://dx.doi.org/10.1155/2014/530830
Research Article

Lower Plasma Creatinine and Urine Albumin in Individuals at Increased Risk of Type 2 Diabetes with Factor V Leiden Mutation

1Department of Internal Medicine, Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, Eberhard-Karls University Tübingen, Otfried-Müller-Straße 10, 72076 Tübingen, Germany
2Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich, University of Tübingen, 72076 Tübingen, Germany
3German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany
4Department of Internal Medicine I and Clinical Chemistry, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
5Department of Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke-University Magdeburg, Leipziger Straße 44, 39120 Magdeburg, Germany

Received 23 November 2013; Accepted 23 December 2013; Published 4 March 2014

Academic Editors: C.-H. Anderwald and J. Vrbikova

Copyright © 2014 Andreas Peter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. W. Majerus, “Bad blood by mutation,” Nature, vol. 369, no. 6475, pp. 14–15, 1994. View at Publisher · View at Google Scholar · View at Scopus
  2. P. G. Lindqvist and B. Dahlbäck, “Carriership of factor V leiden and evolutionary selection advantage,” Current Medicinal Chemistry, vol. 15, no. 15, pp. 1541–1544, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. B. A. Kerlin, S. B. Yan, B. H. Isermann et al., “Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia,” Blood, vol. 102, no. 9, pp. 3085–3092, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Seehaus, K. Shahzad, M. Kashif et al., “Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-cβ-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability,” Circulation, vol. 120, no. 9, pp. 774–784, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Wang, T. Madhusudhan, T. He et al., “Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy,” Blood, vol. 117, no. 19, pp. 5231–5242, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Peter, A. Fritsche, N. Stefan, M. Heni, H.-U. Häring, and E. Schleicher, “Diagnostic value of hemoglobin a1c for type 2 diabetes mellitus in a population at risk,” Experimental and Clinical Endocrinology and Diabetes, vol. 119, no. 4, pp. 234–237, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Matsuda and R. A. DeFronzo, “Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp,” Diabetes Care, vol. 22, no. 9, pp. 1462–1470, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 33, supplement 1, pp. S62–S69, 2010. View at Google Scholar
  9. P. P. Nawroth and B. Isermann, “Mechanisms of diabetic nephropathy—old buddies and newcomers part 1,” Experimental and Clinical Endocrinology and Diabetes, vol. 118, no. 9, pp. 571–576, 2010. View at Publisher · View at Google Scholar · View at Scopus